Bank of America Corp DE lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 2.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,084,176 shares of the company’s stock after selling 25,201 shares during the period. Bank of America Corp DE’s holdings in IDEXX Laboratories were worth $593,109,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in IDEXX Laboratories by 1.9% during the first quarter. BlackRock Inc. now owns 9,162,031 shares of the company’s stock worth $5,012,179,000 after buying an additional 171,445 shares during the period. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,003,012 shares of the company’s stock valued at $4,378,128,000 after purchasing an additional 79,546 shares during the last quarter. State Street Corp lifted its holdings in shares of IDEXX Laboratories by 2.6% during the 4th quarter. State Street Corp now owns 3,743,599 shares of the company’s stock valued at $2,465,010,000 after purchasing an additional 94,327 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,799,521 shares of the company’s stock valued at $1,182,485,000 after purchasing an additional 31,403 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of IDEXX Laboratories by 18.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,596,308 shares of the company’s stock valued at $1,051,105,000 after purchasing an additional 254,033 shares during the last quarter. Hedge funds and other institutional investors own 88.45% of the company’s stock.
IDEXX Laboratories Price Performance
Shares of IDXX opened at $342.56 on Friday. The business’s 50-day moving average is $373.36 and its two-hundred day moving average is $413.90. The company has a market capitalization of $28.52 billion, a P/E ratio of 44.20, a P/E/G ratio of 4.66 and a beta of 1.16. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.61 and a current ratio of 0.89. IDEXX Laboratories, Inc. has a fifty-two week low of $318.50 and a fifty-two week high of $689.95.
Analyst Ratings Changes
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.